Alerta

IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS

Resumen de: WO2026044248A1

Aspects of the present disclosure provide for improved compositions of bioreducible and/or hydrolysable ionizable lipid nanoparticles useful for the delivery of therapeutic nucleic acids and other compounds to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol can be included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells.

IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY TO LUNGS

Resumen de: WO2026042074A1

The present invention provides urea, ester and amide lipids and lipid nanoparticle compositions comprising these urea, ester and amide lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for in vivo therapeutic applications. The lipids of the present invention are characterized as particularly hydrolytically and alcoholytically stable and were found to specifically target the lungs.

TEMPERATURE- AND PH-SENSITIVE, BPA-TARGETED, CHITOSAN-POLY(N-ISOPROPYLACRYLAMIDE)-FPBA CORE-SHELL POLYMERIC NANOPARTICLES CAPABLE OF FORMING COF STRUCTURES FOR USE IN THE BNCT THERAPEUTIC METHOD.

Resumen de: WO2026042111A1

This invention, entitled "Temperature- and pH-Sensitive BPA-Targeted Chitosan-Poly(N-isopropylacrylamide)-FPBA Core-Shell Polymeric Nanoparticles Capable of Forming COF Structures in the BNCT Therapeutic Method," pertains to an anti-cancer pharmaceutical composition utilizing novel drug delivery methods. The application of the novel BNCT method is advantageous for cancers such as glioblastoma due to the challenge of crossing the blood-brain barrier. BNCT is a dual and targeted method wherein cancer cells, following the accumulation of ¹⁰B, are irradiated with thermal neutrons. Loading boron-containing compounds into nanoparticles can deliver a high concentration of boron to human glioblastoma cells. Temperature- and pH-sensitive nanoparticles of succinylated chitosan-poly(N-isopropylacrylamide) targeted with BPA are our concept for achieving endocytosis via sialic acid receptors on the surface of glial cells and for the targeted delivery of boron to these cells. By designing temperature- and pH-sensitive, BPA-targeted Chitosan-Poly(N-isopropylacrylamide)-FPBA core-shell polymeric nanoparticles with the capability of forming COF structures in order to simultaneously deliver BPA and FPBA, we aim to utilize the polymeric boron content to perform treatment via the BNCT method. Consequently, damage to healthy cells is reduced to a minimum, and even to zero.

GASTROINTESTINAL TRACT STABILIZED PROTEIN DELIVERY USING DISULFIDE TES SYSTEM

Resumen de: US20260053945A1

The present invention relates to an engineered disulphide-linked ferritin assembly comprising at least one modified ferritin subunit, wherein the at least one modified ferritin subunit comprises the amino acid sequence set forth in SEQ ID NO: 1, and comprises i) a F116H substitution, and zero or more amino acid substitutions at one or more positions selected from the group comprising E65, E128, E131, and D138 of SEQ ID NO: 1, and ii) a Cys substitution at two or more positions selected from the group comprising G37, L53, R66, G67, A74, A117 and A152 of SEQ ID NO: 1. The present invention also relates to its uses and manufacture.

LIVER ASIALOGLYCOPROTEIN RECEPTOR TARGETED LIPID AND USES THEREOF

Resumen de: WO2025080572A1

A compound having the structure (I), (II), (III), or (IV) is provided: (I), (II), (III), (IV) ) where in these structures, (I), (II), (III), and (IV), each R1 is independently selected from aliphatic alkyl C4-C100 groups optionally substituted with one or more of alkenyl, alkynyl, hydroxyl, amide, ester, and/or ether groups; R2 is selected from -OCH2CH2-p or (A); R3 is selected from Formula (V) and Formula (VI): (V, (VI). M+ is selected from an alkali metal ion, an alkaline earth metal ion, or a primary, secondary or tertiary ammonium ion; and m, p, and s are independently selected from integers from 1 to 120. The compound is useful as a liver asialoglycoprotein receptor-targeted therapeutic agent in the form of a lipid nanoparticle, a liposome or a micelle including a drug or oligonucleotide.

FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING TGFB ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF

Resumen de: AU2024339588A1

Formulated and/or co-formulated liposomes, lipid nanoparticle (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other diseases by utilizing a targeted drug delivery vehicle.

PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Resumen de: US20260055047A1

Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.

COMBINATION THERAPIES

Resumen de: US20260055200A1

The present invention relates to combination therapies for treating cancer, optionally chemotherapy-resistant cancers, in a subject. The combination therapies comprise (a) an antibody or antigen-binding portion thereof that specifically binds to CD40, and (b) chemotherapy. The invention also relates to pharmaceutical compositions, kits and methods of using such therapies.

BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS

Resumen de: US20260055050A1

The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

RESORBABLE SHEET MATERIAL COMPRISING POROUS COLLAGEN SPONGE AND NANOPARTICLES OR MICROPARTICLES WHICH RELEASE ACTIVE INGREDIENTS IN A CONTROLLED MANNER, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF

Resumen de: WO2026041516A1

The invention relates to a profiled sheet material which has a resorbable porous collagen sponge in which resorbable nanoparticles or microparticles or combinations thereof are dispersed, wherein the nanoparticles or microparticles have at least two different release profiles for the controlled and/or delayed release of pharmaceutical active ingredients. The invention further relates to a method for producing the sheet material and to the use thereof in a method for treating wounds or in a method for local pharmacotherapy.

IONIZABLE LIPIDS

Resumen de: AU2024290779A1

The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by formula (I). The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising active agents. It further provides pharmaceutical formulations comprising nanoparticle compositions based on the ionizable lipids disclosed herein.

NOVEL CERIUM OXIDE NANOCOMPOSITE WITH ENHANCED BIOSTABILITY AND USE THEREOF

Resumen de: AU2024296025A1

The present invention relates to a cerium oxide nanocomposite, a method for preparing same, and a composition for the prevention or treatment of inflammatory or autoimmune diseases, comprising same as an active ingredient. The present invention can be used as an excellent therapeutic composition in which both biostability and in vivo efficiency of scavenging reactive oxygen species are maximized by modifying the surface of cerium oxide nanoparticles with an optimal amount of a pyrrolidone derivative polymer. Also, the method for preparing the nanocomposite, of the present invention, can form uniform particles having an optimal diameter while completely removing toxicity caused by reaction residues and nitrate by only a simple process of washing with a sodium chloride solution having a specific concentration. The present invention can be usefully applied to an excellent therapeutic composition which significantly inhibits inflammatory responses in various tissues, and particularly, minimizes damage to nerve cells, caused by excessive inflammatory responses in the periphery of hematoma due to intracerebral hemorrhage, thereby restoring neurological functions and greatly improving the survival rate of patients.

IONIZABLE CATIONIC LIPID COMPOUNDS

Resumen de: US20260055335A1

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.

POLYMER-BASED NANOPLATFORM FOR MRNA DELIVERY TO MULTIPLE CANCER CELL TYPES AND HUMAN INDUCED PLURIPOTENT STEM CELLS

Resumen de: US20260055429A1

A nanoparticle for delivery of mRNA to cell, comprising a core comprising a polyethylenimine polymer having fluorinated groups covalently coupled thereto and with mRNA reversibly associated therewith, and a shell surrounding the core comprising heparin. Ij some embodiments, the nanoparticle comprises a targeting agent associated with the shell, wherein the targeting agent is selected from the group consisting of agents that bind to receptors overexpressed on tumor cells, agents that bind to cell surf ace antigens that are expressed on pluripotent stem cells, agents that bind to cell surface antigens on T cells, and agents that bind to antigens presented by MHO molecules. Pharmaceutical compositions that include the nanoparticle and methods for using the nanoparticle for transfecting cells are provided

PROGRAMMABLE NUCLEASE RESISTANCE OF NUCLEIC ACID ASSEMBLIES

Resumen de: US20260053933A1

The present invention provides nuclease-resistant nucleic acid nanostructures, pharmaceutical compositions thereof, pharmaceutical and diagnostic uses thereof as well as a method of producing nucleic acid nanostructures.

FREEZE-DRIED NANODROPLETS WITH FLUORINATED COMPOUND

Resumen de: US20260053957A1

The present invention generally relates to the field of ultrasound contrast-agents (USCA). In particular, it relates to a freeze-dried composition comprising an amphiphilic lipid compound comprising a phospholipid, a fluorinated compound in liquid form and a freeze-drying protecting component which may be reconstituted for preparing a suspension of nanodroplets useful in diagnostic or therapeutic applications. It further relates to the method for the preparation of such freeze-dried composition.

PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE

Resumen de: US20260054267A1

The present invention relates to methods for producing particles of a biologically active material using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments.

DNA ORIGAMI VACCINES

Resumen de: US20260053906A1

Disclosed herein is a vaccine device that involves a DNA origami nanostructure formed from a plurality of scaffold strands and a plurality of staple strands assembled into a rod shape, wherein a peptide antigen is attached to the DNA of the nanostructure by electrostatic interaction. Also disclosed herein is a method for vaccinating a subject that involves administering to the subject a therapeutically effective amount of a vaccine device disclosed herein.

PHARMACEUTICAL COMPOSITIONS OF SPIRONOLACTONE FOR DEEP DERMAL DRUG DELIVERY

Resumen de: US20260053821A1

Pharmaceutical compositions for the topical administration of spironolactone to the pilosebaceous unit and methods for administering the same. The pharmaceutical compositions comprise aqueous suspensions of submicron particles of spironolactone in water.

COMPOSITIONS AND METHODS OF USE THEREOF FOR PREVENTION OF MASTITIS

Resumen de: US20260053746A1

Disclosed herein are compositions and methods of use thereof for the prevention of mastitis in dairy cattle. The compositions and methods can have immunostimulant effectiveness against mastitis-causing bacteria. In particular embodiments, the methods include preventing mastitis infection by intramammary infusion of a disclosed composition at dry-off.

METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY

Resumen de: US20260053737A1

In one aspect, the disclosure relates to relates to compositions, devices, and processes for drug delivery to an eye. The disclosed drug delivery compositions comprise a particle having a core component comprising a first polymer and a therapeutic agent, and a shell layer surrounding the core component comprising a second polymer. In a further aspect, the present disclosure relates to methods of treating an ophthalmological disease or disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

PARENTERAL COMPOSITIONS OF ZILEUTON AND METHODS OF USE

Resumen de: US20260053774A1

Provided herein are compositions containing zileuton formulated for parenteral administration and/or extended use. Methods of treatment are directed to subjects who would benefit from extended use of zileuton to provide renal protective effects.

Sustained Nitric Oxide Releasing Drug Delivery Systems

Resumen de: US20260053768A1

Disclosed herein are drug delivery vehicle compositions, comprising lipid nanoparticle-forming molecules, a nitric oxide donor (NO-donor) molecule, and a hydrogel. Also disclosed are methods of making the same by mixing the lipid nanoparticle-forming molecules and the NO-donor in a hydrophobic solvent to form a first mixture; and adding a mixture of hydrogel and water, and optionally a buffer solution, to the first mixture to form the drug delivery vehicle composition. In addition, disclosed herein are methods of treating a patient suffering from a disease that can be treated with nitric oxide, the method comprising identifying a patient in need thereof, and administering to the patient a drug delivery vehicle disclosed herein.

NANOCOMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE AND USE THEREOF

Resumen de: US20260053943A1

This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a targeting bioactive agent (TBA); a payload bioactive agent (PBA) covalently linked to the targeting bioactive agent (TBA) directly or indirectly; and, optionally, a polymer forming nanoaggregates. The pharmaceutical composition can comprise Ag+ tumor cytotoxicity to tumor cells having a tumor antigen (Ag+ tumor cells) and Ag− tumor cytotoxicity to tumor cells free from a tumor antigen (Ag− tumor cells). The pharmaceutical composition can be an antibody-drug conjugate (ADC) for treating cancers having tumor antigen positive (Ag+) tumor cells, tumor antigen negative (Ag−) tumor cells, or heterogenous cancers having both tumor antigen positive (Ag+) tumor cells and tumor antigen negative (Ag−) tumor cells.

OXIDIZED CARBON PEG-OAC NANOZYMES FOR MITOCHONDRIAL DISORDERS

Nº publicación: US20260053946A1 26/02/2026

Solicitante:

THE TEXAS A&M UNIV SYSTEM [US]
The Texas A&M University System

Resumen de: US20260053946A1

The present invention is directed to a composition and a method for treating a mammal exhibiting an inherited mitochondrial disease. That method comprises administering a pharmaceutical composition containing a mitochondria-treating effective amount of PEG-OAC nanozymes, DEF-OAC-PEG nanozymes or both nanozymes dissolved or dispersed in a physiologically tolerable diluent. In that composition, PEG is an acronym for a reacted alpha-amino-omega-methoxy-poly(ethylene glycol) substituent, OAC is an acronym for oxidized activated charcoal particle, and DEF is an acronym for a reacted deferoxamine substituent. Both of the PEG and the DEF substituents are each covalently bonded to the OAC particle by the primary amino group on each.